AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00938769 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Comparison Conditions for Caregivers
Description: Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for caregiving.~2-hour counseling session for cancer caregivers to locate community support resources
Study NCT04328038 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Patient fill out a survey containing: Demographic Information, medical history, several Questionnaires about Health Literacy, Well Being/HRQoL and Fatigue
Study NCT00288626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF) and prednisone
Description: Growth factor regimen; occurs at study entry
Study NCT00288626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine, etoposide, cytarabine, and melphalan (BEAM)
Description: High-dose chemotherapy; occurs seven or more days following collection of autologous graft
Study NCT00288626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplant
Description: Occurs after growth factor regimen and collection of autologous graft
Study NCT01446536 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Checklist cohort
Description: CHF discharge checklist was used arbitrarily by their treating physicians in addition to the standard therapy
Study NCT03525223 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Change of dialysate [Na+]
Description: Stepwise modulation of dialysate sodium concentration by 1-2 mmo/l per week
Study NCT02021344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid
Description: Originally developed in 2001, MHFA is a 12-hour course comprised of six modules, covering depression, anxiety, psychosis, substance abuse, eating disorders, and self-harm. Each module includes information about the mental health-related problems (e.g., signs and symptoms), advice on how to respond appropriately, and interactive activities to enhance the learning process. Some modules include videos with perspectives of individuals recovering from mental disorders and examples of how to effectively use the MHFA intervention. Program participants learn how to help individuals in crisis and also how to recognize early warning signs and intervene before mental health problems progress to crises.
Study NCT00991237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency
Description: Pulsed Radiofrequency
Study NCT02063477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo composition is for 1 gelule: 250 mg maltodextrin + 30 mg magnesium stearate; total weight: 280 mg/gelule
Study NCT02063477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oligopin®
Description: Oligopin® PUR' expert (%) is a red brown powder extracted from the bark of the Maritime Pine (Pinus pinaster) with composition:~- TOTAL POLYPHENOL CONTENT > 96~1. MONOMERS + PHENOLIC ACIDS 30~2. DIMERS >15~3. OTHER OLIGOMERS 50~PROCYANIDINS CONTENT (GPC) > 67~The Oligopin composition is for 1 gelule: 75 mg Oligopin + 175 mg maltodextrine + 30 mg magnesium stearate: total weight: 280 mg/gelule
Study NCT03107039 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: A 12 week resistance exercise curriculum
Study NCT03107039 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: A 12 week health education curriculum
Study NCT02721277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFlipid
Description: SMOFlipid contains a mixture of 4 different lipid sources: soybean oil which provides essential fatty acids, olive oil which is high in monounsaturated fatty acids that are less susceptible to lipid peroxidation than polyunsaturated fatty acids, medium-chain triglycerides which show a faster metabolic clearance than long-chain triglycerides, and fish oil which provides the supply of omega-3 fatty acids.
Study NCT02613832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EPAP
Description: The EPAP will be applied with a Spring Load Valve Resistor (Vital Signs, Totowa, NJ, USA), adjusted with a pressure of 10 cmH2O. The Spring Load Valve Resistor will be connected to the expiratory branch of the T-tube. Duration of intervention: 5 minutes.
Study NCT02613832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath Stacking
Description: The BS will be performed by a T-tube with a one-way inspiratory valve and the expiratory branch occluded. The expiratory occlusion is maintain until observed the presence of a plateau in the impedance plethysmogram by EIT, which corresponds to the absence of inspired air displacement or when a maximum time of 40 seconds was attained. Durantion of intervention:Three BS interventions will be performed at one minute intervals between them.
Study NCT03070600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Universal PrEP Counseling
Description: Counseling at universal sites, will use a standardized counseling script to state that PrEP is available for women at risk for HIV, explain that HIV prevalence in the region is high, and will note that women with HIV positive partners or who don't know their partner's status may be at risk. Counseling will specify that women may have their own reasons to feel at risk or to want PrEP. Following standardized counseling, women will select PrEP at the same visit or will be allowed to deliberate on the decision and come back at the next visit with a decision. Women will be informed that it is advisable to use PrEP if they know their partner is HIV positive or if they do not know their partner's status and will be encouraged to bring untested partners to clinic if status is unknown.
Study NCT03070600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted PrEP Counseling
Description: Following enrollment, the targeted PrEP clinics will provide two inter-related innovations over two ANC visits. In the targeted PrEP clinics, any of the following three criteria can trigger enhanced PrEP counseling. A participant that meets any one of these criteria will receive PrEP counseling during the study visit where the criteria is met:~1. Risk Score >6 (Risk score includes male partner status known/unknown, syphilis infection, and lifetime number of male partners) or any National AIDS and STI Control Programme (NASCOP) risk factors~2. participant declines partner self-tests regardless of partner HIV status, and/or~3. their partner declines self-testing or tests positive.
Study NCT00003909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: motexafin gadolinium
Description: Given IV
Study NCT00003909 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00003909 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlatives studies
Study NCT03538860 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Active comparator: Human interpreter
Description: A Spanish-speaking patient is diagnostically assessed in-person by an English-speaking psychiatrist through a Spanish-speaking interpreter.
Study NCT03538860 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention: Asynchronous Telepsychiatry
Description: A Spanish-speaking patient is interviewed in Spanish by a trained mental health interviewer. The interview is video-recorded in real-time, automatically translated into English with sub-titles added to the video file, and sent to a psychiatrist and to 3 English-speaking psychiatrists to asynchronously review the video and make a diagnosis.
Study NCT04341493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500 MG
Description: Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with two drugs
Study NCT04341493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with one drug
Study NCT04341493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Clinical evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using this option with one drug
Study NCT03981380 — intervention group
Intervention type: DRUG
Intervention: 11C-PIB
Description: Participants will be injected with an intravenous bolus of up to 5-15mCi (370 MBq) (+/-10%) of \[11C\]PiB (over 5-10 seconds).
Study NCT03790501 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: As an observational study, no intervention will be associated with the study group.
Study NCT01487395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil .
Description: Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
Study NCT01487395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the placebo will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
Study NCT03895008 — intervention group
Intervention type: OTHER
Intervention: Cardia and Non-cardia gastric cancer
Description: We classify gastric cancer into cardia gastric cancer and non-cardia gastric cancer.
Study NCT04005404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine (sciatic nerve block)
Description: injection of 20 ml ropivacaine 0.375%
Study NCT04005404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine (lumbar plexus block L2-L4)
Description: injection of 20 ml ropivacaine 0.375%
Study NCT04005404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine (lumbar plexus block Th12-L1)
Description: injection of 20 ml ropivacaine 0.375%
Study NCT00753285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Study NCT00660257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic influenza vaccine (H5N1 strain NIBRG-14)
Description: pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
Study NCT00660257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic influenza vaccine (H5N1 strain NIBRG-14)
Description: pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 2.5 ug per dose, intramuscular injection
Study NCT00660257 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pandemic influenza vaccine (H5N1 strain NIBRG-14)
Description: pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 5.0 ug per dose, intramuscular injection
Study NCT01237171 — intervention group
Intervention type: RADIATION
Intervention: Cesium-131 Brachytherapy Seed
Description: 85 Gray Dose
Study NCT01227590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)
Description: The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
Study NCT01277627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nevirapine
Description: nevirapine: 400 mg a day.
Study NCT01277627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz, protease inhibitors
Description: efavirenz: 600 mg a day
Study NCT01074801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop insulin delivery
Description: Basal subcutaneous insulin delivery to be adjusted at 15min cycles according to the computer-based algorithm advice.
Study NCT01074801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard insulin pump treatment
Description: Subcutaneous insulin delivery to be performed based on subjects' standard treatment
Study NCT02037178 — intervention group
Intervention type: OTHER
Intervention: First ultrasound reading
Description: First ultrasound reading of the sub-renal abdominal aorta by a general practitioner.
Study NCT02037178 — intervention group
Intervention type: OTHER
Intervention: Second ultrasound interpretation
Description: The untrasound images recorded by general practitioners will be interpreted a second time by an expert in vascular medecine, and evaluated for their image quality.
Study NCT04412655 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous Coronary Revascularization for STEMI
Description: Percutaneous Mechanical Reperfusion for STEMI
Study NCT00317187 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Meningitec conjugate vaccine
Description: The full content of two monodose vials of Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Meningitec (5/5/5) vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): one dose of 0.5 ml of the reconstituted Tritanrix- HepB/Meningitec vaccine was withdrawn from the vial and administered, the needle was changed before injection
Study NCT00317187 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix/Hiberix vaccine
Description: The full content of the Tritanrix-HepB vaccine vial was extracted and injected into the vial containing the lyophilized Hiberix vaccine. The vial was agitated until the lyophilized vaccine pellet had completely dissolved. The reconstituted mixed vaccines were used promptly after reconstitution (within 30 minutes): the full volume of the mixed vaccines was withdrawn from the vial, the needle was changed before injection.
Study NCT00462709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1 esterase inhibitor [human] (C1INH-nf)
Study NCT02531308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin upregulates AMPK activity which has been shown to have an anti-proliferative effect on lymphoma cells.
Study NCT02531308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: monoclonal antibody against protein CD20 primarily found on the surface of B-cells
Study NCT02531308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Interferes with DNA replication
Study NCT02531308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: anthracycline antitumor antibiotic
Study NCT02531308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Inhibits cell mitosis causing cell death.
Study NCT02531308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. It is used to treat certain inflammatory diseases
Study NCT02531308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: stimulates the level of white blood cells (neutrophils).
Study NCT02180529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention.
Study NCT02180529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02646540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg + IV Diuretics
Description: Participants will receive oral daily tolvaptan 30 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
Study NCT02646540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metolazone 5 mg + IV Diuretics
Description: Participants will receive oral daily metolazone 5 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
Study NCT02646540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5 times the Diuretics Dose
Description: Participants will receive two and a half (2.5) times their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
Study NCT03608033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OMS721
Description: Biological: OMS721
Study NCT03608033 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (D5W or saline)
Description: 5% Dextrose in water or normal saline solution
Study NCT02364830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anise-oil EC Capsule
Description: Anise-oil EC Capsule,One Cap(187mg)/day for 4 Weeks
Study NCT02364830 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One Placebo Capsule/Day for 4 Weeks
Study NCT02364830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colpermin®
Description: Colpermin® Capsule/Day for 4 Weeks
Study NCT04394234 — intervention group
Intervention type: DRUG
Intervention: Direct oral anticoagulant (DOACs)
Description: Data of participants newly exposed to individual DOACs that is rivaroxaban, apixaban, dabigatran from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.
Study NCT04394234 — intervention group
Intervention type: DRUG
Intervention: Warfarin
Description: Data of participants newly exposed to warfarin from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.
Study NCT02318680 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Review of follow home visits after discharge from Nykøbing Falster Hospital
Description: The intervention is follow home visits which is randomized and is an intervention that is assigned by the investigator.
Study NCT01599260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Two 30-minute individually supervised exercise sessions per week for 16-weeks
Study NCT03107390 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluate the blood level of NTproBNP
Description: Evaluate the blood level of NTproBNP in patients with MICI compared to a healthy control population.
Study NCT02989870 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Participants will receive 3-5 fractions of radiation as determined by the dose level at time of enrollment. The starting dose level will be Dose Level 1: 8 Gy x 3 fractions for a total of 24 Gy. If sufficient treatment related toxicity is observed at the initial starting dose, then the dose will be reduced to 16 Gy in 2 fractions of 8 Gy. The dose per fraction for each participant will be provided at the time of registration based on the toxicity experience of the previous participants on study. This will be escalated to 40 Gy in 5 fractions of 8 Gy.
Study NCT02989870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib by mouth (PO): 200 mg twice a day (BID) then 400 mg BID.
Study NCT02989870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab intravenously (IV): 3 mg/kg every week (q wk).
Study NCT04168723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MD1003
Description: Group A: Daily dose of 1200 mg of MD1003 from Day 1 to Day 8
Study NCT04168723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: Group B1: Moxifloxacin 400 mg on Day 1 Group B2: Moxifloxacin 400 mg on Day 9
Study NCT04168723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MD1003
Description: Group A: Placebo for MD1003 on Day -1 Group B1: Placebo for MD1003 on Day -1 Group B2: Placebo for MD1003 on Day -1
Study NCT04168723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for MD1003
Description: Group A: Placebo for MD1003 on Day -1 Group B1: Placebo for MD1003 on Day -1 Group B2: Placebo for MD1003 on Day -1
Study NCT04168723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for moxifloxacin
Description: Group A: Placebo for moxifloxacin on Day 1 and Day 9 Group B1: Placebo for moxifloxacin on Day 9 Group B2: Placebo for moxifloxacin on Day 1
Study NCT04168723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for moxifloxacin
Description: Group A: Placebo for moxifloxacin on Day 1 and Day 9 Group B1: Placebo for moxifloxacin on Day 9 Group B2: Placebo for moxifloxacin on Day 1
Study NCT01226966 — intervention group
Intervention type: DRUG
Intervention: liraglutide
Description: Prescription is done at the discretion of the prescribing physician as part of normal clinical routine.
Study NCT00002772 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00002772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00002772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Study NCT00002772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00002772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00002772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00002772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00002772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Study NCT00002772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Study NCT00002772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow transplantation